Key Highlights
- Serina Therapeutics shares rocketed 39.45% in after-hours trading, reaching $1.78 from a regular session close of $1.28.
- A $15 million private placement is scheduled to close March 20, with an additional $15 million tranche expected by April 30.
- Full warrant exercise could generate another $33.3 million, potentially funding operations through late 2027.
- Shares are being sold at $2.25 each — representing a 68% premium over the March 17 closing price.
- Greg Bailey, a board member with ties to Pfizer’s $11.6B Biohaven and $14B Medivation acquisitions, will assume the role of Co-Chairman.
Serina Therapeutics (SER) shares exploded nearly 40% in extended trading Wednesday following the biotech firm’s announcement of a private placement that could yield as much as $63.3 million in total capital.
Serina Therapeutics, Inc., SER
The dramatic after-hours rally occurred shortly after regular trading ended, when Serina disclosed that an initial $15 million tranche would close around March 20, 2026. A subsequent tranche of up to $15 million is expected to finalize on or before April 30.
Shares climbed from $1.28 at the regular session close — which reflected a 4.48% decline — to $1.78 during after-hours activity.
The financing is structured at $2.25 per share, marking a significant 68% premium to the closing price on March 17. Each unit includes either a common share or pre-funded warrant, paired with a half-warrant exercisable at $5.00 per share. These warrants carry a four-year expiration and could inject an extra $33.3 million if fully exercised, bringing total potential proceeds to $63.3 million.
For a clinical-stage biotechnology firm, this capital infusion is critical. Serina projects the funding will sustain operations well into the latter half of 2027.
Veteran Investor Takes Co-Chairman Role
The financing round is being spearheaded by Greg Bailey, M.D., a sitting board member who will now assume the position of Co-Chairman alongside current chair Simba Gill, Ph.D.
Bailey’s credentials are impressive. He was an early investor in Biohaven Ltd., which Pfizer acquired in 2022 for roughly $11.6 billion, and Medivation, purchased by Pfizer in 2016 for $14 billion.
This background resonated with the investment community. When a figure like Bailey leads a financing initiative — particularly in the biotech sector — it often signals confidence to the market.
Funding Allocation Details
The capital raised will primarily support Serina’s SER-252 registrational study, an active Phase 1b clinical trial focused on advanced Parkinson’s disease. Patient enrollment is underway at multiple locations across Australia and the United States.
SER-252 is advancing through the FDA’s 505(b)(2) regulatory framework, which CEO Steve Ledger characterized as a “capital-efficient” development approach. The trial has already dosed its first participant.
Serina anticipates that safety data from Cohort 1 will enable progression to Cohort 2 during Q3 2026. Top-line results from the single-ascending dose phase are projected for the first half of 2027.
The therapeutic candidate addresses a patient population of roughly 250,000 individuals with advanced Parkinson’s disease in the U.S. and Europe whose symptoms remain insufficiently managed by existing treatment options.
Despite Wednesday’s post-market surge, SER’s broader performance trend presents challenges. The stock has traded between $1.22 and $7.92 over the past 52 weeks and has dropped 71.11% year-over-year. The company’s market capitalization currently stands at merely $13.65 million, while its RSI of 29.86 indicates severely oversold conditions.
SER concluded Wednesday’s regular trading session at $1.28, down 4.48% for the day.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
